Phase 2 Study to Evaluate Dose Optimization and Anti-tumor Activity of Atebimetinib in Participants With Advanced or Metastatic NSCLC.
A Phase 2, Open-Label, Multicenter, Dose Optimization and Anti-Tumor Activity Study of Atebimetinib, a Novel Oral Dual MEK1/2 Inhibitor in Combinations With Cemiplimab and Chemotherapy in First Line, RAS-mutated, Locally Advanced or Metastatic NSCLC Participants
Atebimetinib Plus Cemiplimab, With or Without Chemotherapy, in First-Line RAS-Mutated Non-Small Cell Lung Cancer
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Contact
Study Contact
- Name: IMM1104-201 Study Team
- Phone Number: (860) 321-1302
- Email: clinicaltrials@immuneering.com
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Aged 18 years or older
- Nnon-squamous NSCLC, stage IIIB or stage IV, with no prior systemic treatment for recurrent or metastatic disease. Prior adjuvant or neoadjuvant platinum therapy is allowed if completed more than 6 months before recurrence.
- Measurable disease (at least 1 target lesion) per RECIST 1.1.
- ECOG performance status of 0 or 1.
- PD-L1 score determined by an FDA-approved test.
- RAS-mutated NSCLC documented by next-generation sequencing (NGS), performed locally per institutional standards. Results must be available before enrollment. Liquid biopsy is acceptable.
- Adequate organ function:
Exclusion Criteria:
- Inability to swallow oral medications.
- EGFR, ALK or ROS1 mutation.
- Untreated or unresolved brain metastases
- Encephalitis, meningitis or uncontrolled seizures in the year before informed consent.
- History of interstitial lung disease non-infectious pneumonitis that required immunosuppressive doses of glucocorticoids, or any pneumonitis within the last 5 years. Radiation pneumonitis in the radiation field is permitted.
- Active autoimmune disease that required systemic treatment in the past 12 months.
- A condition requiring corticosteroids >10 mg/day prednisone or equivalent within 14 days of Cycle 1 Day 1.
- Prior allogeneic tissue or solid organ transplant.
- Never-smoker (fewer than 100 cigarettes in a lifetime).
- Prior anti-PD-1 or anti-PD-L1 therapy.
- Impaired cardiac function or clinically significant cardiac disease, including left ventricular ejection fraction <50% by ECHO or MUGA or screening QTcF >470 msec.
- History of serous retinopathy, retinal edema or retinal pigment epithelial detachment.
- History or current evidence of retinal vein occlusion (RVO), or current RVO risk factors.
- Rhabdomyolysis within 3 months before Study Day 1.
- Major surgery or significant traumatic injury within 4 weeks before the first dose.
- Another malignancy.
- Any infection requiring hospitalization or IV anti-infectives within 2 weeks before the first dose.
- Uncontrolled HIV, hepatitis B or hepatitis C infection; immunodeficiency; or active or latent tuberculosis.
- Live vaccine within 4 weeks before the first dose.
- COVID-19 vaccination within 1 week before the planned first dose, or a planned COVID-19 vaccination series that won't be completed at least 1 week before the first dose.
- Known hypersensitivity to any study drug or excipient.
- Unwillingness to use effective contraception
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Atebimetinib + Cemiplimab ± Chemotherapy
Participants receive atebimetinib orally once daily (160, 240 or 320 mg) plus cemiplimab 350 mg IV every 3 weeks. Carboplatin and pemetrexed are given IV every 3 weeks for 4 cycles in the dose optimization portion, and in the expansion portion for participants with PD-L1 <50%. The expansion uses the atebimetinib dose selected during dose optimization. |
Oral dual MEK1/2 inhibitor, immediate-release tablets, given once daily continuously at 160, 240 or 320 mg
Other Names:
Anti-PD-1 monoclonal antibody, 350 mg IV every 3 weeks
Other Names:
AUC 5 or 6 mg/mL/min IV (Calvert formula) on Day 1 of Cycles 1-4 500 mg/m² IV on Day 1 of Cycles 1-4
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maximum Plasma Concentration (Cmax), Time to Maximum Plasma Concentration (Tmax) and Area under the curve (AUC0-t) of Atebimetinib
Time Frame: Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.
|
Measured in dose optimization |
Cycle 1 Day 1 Cycle 2 Day 1 Each cycle is 21 days.
|
|
Objective Response Rate (ORR)
Time Frame: Every 8 weeks, up to approximately 24 months
|
Percentage of participants with complete or partial response per RECIST 1.1 |
Every 8 weeks, up to approximately 24 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Median Progression-Free Survival (PFS)
Time Frame: Up to approximately 24 months.
|
Time from Cycle 1 Day 1 to first documented disease progression per RECIST v1.1 or death from any cause, whichever comes first. |
Up to approximately 24 months.
|
|
Overall Survival (OS)
Time Frame: From Cycle 1 Day 1 (each cycle is 21 days) until death from any cause, assessed every 12 weeks after treatment ends. Up to approximately 36 months.
|
Time from Cycle 1 Day 1 to death from any cause. |
From Cycle 1 Day 1 (each cycle is 21 days) until death from any cause, assessed every 12 weeks after treatment ends. Up to approximately 36 months.
|
|
Number of Participants with adverse events
Time Frame: From first dose on Cycle 1 Day 1 through 90 days after the last dose. Each cycle is 21 days.
|
Treatment-emergent and treatment-related AEs per CTCAE v6.0 |
From first dose on Cycle 1 Day 1 through 90 days after the last dose. Each cycle is 21 days.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Vinny Hayreh, Immuneering Corporation
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Site
- Neoplasms
- Respiratory Tract Diseases
- Lung Diseases
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma, Non-Small-Cell Lung
- Amino Acids, Peptides, and Proteins
- Organic Chemicals
- Heterocyclic Compounds
- Heterocyclic Compounds, 2-Ring
- Heterocyclic Compounds, Fused-Ring
- Coordination Complexes
- Guanine
- Hypoxanthines
- Purinones
- Purines
- Glutamates
- Amino Acids, Acidic
- Amino Acids
- Amino Acids, Dicarboxylic
- Pemetrexed
- Carboplatin
- cemiplimab
Other Study ID Numbers
Other Study ID Numbers
- IMM1104-201
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.